Skip to main content

Table 2 Summary of 20 benign lesions in 20 patients

From: Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

Benign lesion number Histopathology L/B ratio Assessment
99mTc sestamibi 99mTc maraciclatide 99mTc sestamibi 99mTc maraciclatide
1 ADH 1.24 1.28 3 3
2 ADHa Not seen 1.34 1 4
3 Benign fibrocystic changes Not seen Not seen 1 2
4 Benign fibrocystic changes Not seen Not seen 1 1
5 Benign fibrocystic changes Not seen Not seen 1 2
6 Benign fibrocystic changes Not seen Not seen 1 1
7 Benign fibrocystic changes Not seen Not seen 1 2
8 Benign fibrocystic changes Not seen Not seen 1 1
9 Fibroadenoma 1.52 1.35 3 3
10 Fibroadenoma Not seen Not seen 1 2
11 Fibroadenoma Not seen Not seen 1 1
12 Fibroadenoma Not seen Not seen 1 2
13 Fibroadenoma 1.24 1.13 3 4
14 Fibroadenoma 1.14 1.25 2 3
15 Fibroadenomab 1.12 1.11 4 4
16 Inflammatory tissue 1.25 1.36 4 4
17 Intramammary lymph node 1.14 Not seen 4 2
18 Papilloma Not seen Not seen 2 2
19 Papilloma 1.07 1.13 2 2
20 PASH 2.35 2.76 2 2
  1. ADH atypical ductal hyperplasia, PASH pseudoangiomatous stromal hyperplasia
  2. aPatient with invasive ductal carcinoma had ADH diagnosed in the contralateral breast
  3. bPatient with invasive ductal carcinoma had a fibroadenoma in the ipsilateral breast